Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Cash from Operations (2016 - 2026)

Ocular Therapeutix has reported Cash from Operations over the past 14 years, most recently at 65993000.0 for Q1 2026.

  • For Q1 2026, Cash from Operations fell 47.73% year-over-year to 65993000.0; the TTM value through Mar 2026 reached 226205000.0, down 55.51%, while the annual FY2025 figure was 204883000.0, 52.13% down from the prior year.
  • Cash from Operations for Q1 2026 was 65993000.0 at Ocular Therapeutix, down from 54249000.0 in the prior quarter.
  • Over five years, Cash from Operations peaked at 7732000.0 in Q3 2023 and troughed at 65993000.0 in Q1 2026.
  • A 5-year average of 31493529.41 and a median of 24802000.0 in 2024 define the central range for Cash from Operations.
  • Biggest five-year swings in Cash from Operations: soared 45.77% in 2022 and later tumbled 372.83% in 2024.
  • Year by year, Cash from Operations stood at 16958000.0 in 2022, then crashed by 32.41% to 22454000.0 in 2023, then plummeted by 75.6% to 39429000.0 in 2024, then plummeted by 37.59% to 54249000.0 in 2025, then dropped by 21.65% to 65993000.0 in 2026.
  • Business Quant data shows Cash from Operations for OCUL at 65993000.0 in Q1 2026, 54249000.0 in Q4 2025, and 50725000.0 in Q3 2025.